HIV i-Base is a treatment activist group, HIV-positive led and committed to providing timely HIV treatment information both to positive people and to health care professionals.
This includes technical publications like HIV Treatment Bulletin (HTB) and ARV4IDUs (Antiretrovirals for Injecting Drug Users) and non-techical treatment guides on starting and changing treatment, side effects, hepatitis C coinfection and HIV and pregnancy.
i-Base is involved in several community networks, including the UK Community Advisory Board (UK-CAB), the European AIDS Treatment Group (EATG), the European Community Advisory Board (ECAB) and the International Treatment Preparedness Coalition (ITPC) and the AIDS Treatment Activists Coalition (ATAC).
We have also developed close working relationships with NGOs in many different countries in Western and Eastern Europe and Africa. Copyright free i-Base material has been produced in over 40 languages.
We are directly involved in research with INSIGHT network, PENTA network, MRC studies in the UK, Metabolic Oversight Committee and D:A:D studies.
Treatment guides and i-Base authored articles in HTB may be reproduced by NHS, community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original source on the i-Base Web site is always appreciated. All i-Base material remains the copyright of HIV i-Base.
HIV i-Base receives unconditional educational grants from charitable trusts, individual donors and pharmaceutical companies. All editorial policies are strictly independent of funding sources.
HIV i-Base is a registered charity no.1081905 and company limited by guarantee no. 3962064.
How to Reach HIV i-Base
57a Great Suffolk Street
Latest by HIV i-Base
The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants
The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.
The U.S. FDA has approved Temixys, a generic combination tablet of tenofovir disoproxil fumarate plus lamivudine.
"Undetectable equal untransmittable" is sometimes wrongly interpreted as covering all ways that HIV can be transmitted.
Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.
HIV Diagnoses in UK Drop for Third Year: Among All Ages, Risk Groups, and Ethnicities and Across Most UK Regions
Preliminary data released by Public Health England show that HIV diagnoses dropped by 17% in 2017 compared to 2016.